However, the guidelines applied for the validation of the method were not updated, and there is no information about ALL patients; moreover, we demonstrated for our method, a higher sensitivity (30 pmol/8 × 108 RBC) for TGN compared to what had been described previously. The gene discussed is TG; the disease is acute lymphoblastic leukemia.